Physician profile
Kenneth Ahdoot
NPI 1013017524
$2,116.55
in general payments reported to CMS, 2019-2025
21 companies · $966 in 2025
The $966 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $112 · 2021: $176 · 2022: $19.12 · 2023: $212 · 2024: $153 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $875 · Food and Beverage: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $875.00 |
| Food and Beverage | $455.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Winter & Ibe Gmbh | $875.00 | 2025 | Endoeye Flex Deflectable Videoscope |
| Bayer Healthcare Pharmaceuticals INC. | $355.47 | 2019-2023 | |
| Abbvie INC. | $141.17 | 2019-2021 | |
| Sanofi Pasteur INC. | $136.00 | 2023 | |
| Organon LLC | $75.39 | 2024-2025 | |
| Aspira Women'S Health INC | $75.00 | 2021 | |
| Lupin INC. | $71.74 | 2019-2020 | |
| Pfizer INC. | $59.42 | 2024 | |
| Coopersurgical, INC. | $58.06 | 2019-2022 | |
| Therapeuticsmd, INC. | $41.88 | 2019-2020 | |
| Astellas Pharma US INC | $33.54 | 2024 | Veozah |
| Myriad Genetic Laboratories, INC. | $33.54 | 2023 | Myrisk |
| Dexcom, INC. | $25.21 | 2025 | Dexcom G6 Transmitter |
| Exeltis, USA INC. | $24.60 | 2020 | |
| Optumhealth Care Solutions, LLC | $22.06 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $19.25 | 2019 | |
| Avion Pharmaceuticals | $15.89 | 2019 | |
| Millicent US INC | $14.60 | 2024 | Femring, Intrarosa |
| Mayne Pharma Commercial LLC | $13.51 | 2025 | |
| Zyla Life Sciences, INC. | $13.12 | 2020 | |
| Meditrina | $12.10 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Ahdoot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.